SCHEMBL35210874

SCHEMBL35210874

Cc1cc(NC(=O)OC(C)(C)C)n(C)n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.57
MAPK14 Q16539 2/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
KDM4E B2RXH2 1/20 0.45
HTT P42858 1/20 0.45
BRD9 Q9H8M2 1/20 0.41
POLB P06746 1/20 0.40
PKM P14618 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA9 Q16790 1/20 0.40
KDM1A O60341 1/20 0.40
ATM Q13315 1/20 0.40
GAA P10253 1/20 0.38
CCNC P24863 1/20 0.38
CDK8 P49336 1/20 0.38
NTRK1 P04629 1/20 0.38
LCK P06239 1/20 0.38
GSK3B P49841 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6845100 0.84 MAPK14 (0.48) SMN1; SMN2MAPK14MEN1KMT2ABRD9
SCHEMBL798842 0.83 GAA (0.49) SMN1; SMN2MAPK14MEN1KMT2ABRD9
SCHEMBL19271750 0.83 MAPK14 (0.47) SMN1; SMN2MAPK14BRD9CA1CCNC
SCHEMBL19300006 0.83 MAPK14 (0.47) SMN1; SMN2MAPK14BRD9CA12CA1
SCHEMBL2175532 0.83 MAPK14 (0.47) SMN1; SMN2MAPK14BRD9CA1CCNC
SCHEMBL25408156 0.81 MAPK14 (0.46) SMN1; SMN2MAPK14KDM4EBRD9GSK3B
SCHEMBL21597704 0.81 MAPK14 (0.46) SMN1; SMN2MAPK14KDM4EBRD9GAA
SCHEMBL25407400 0.80 MAPK14 (0.46) SMN1; SMN2MAPK14BRD9PKMCCNC
SCHEMBL25401903 0.79 MAPK14 (0.45) SMN1; SMN2MAPK14KMT2AKDM4EGAA
SCHEMBL7532390 0.78 SMN1; SMN2 (0.62) SMN1; SMN2MAPK14MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125389-A1 MEMBRANE-ASSOCIATED TYROSINE AND THREONINE KINASE INHIBITOR AND USE THEREOF HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO LTD (CN) 2026-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125389-A1 MEMBRANE-ASSOCIATED TYROSINE AND THREONINE KINASE INHIBITOR AND USE THEREOF PKMYT1, PKN1, ROS1 SMN1; SMN2 1480/4885MAPK14 121/4885MEN1 1426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.